Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saccharomyces Boulardii CNCM I-745 for Growth in Preterm Infants
NCT02310425Phase 3Completed
- Start
- Mar 2013
- Primary completion
- Jul 2013
- Modality
- Microbiome Therapeutics
01
Overview
Phase 3, randomised, single-blind trial of saccharomyces boulardii in preterm birth (2 arms). Primary endpoint: Weight at 28 days. Started Mar 2013; status: completed.
02
Drugs
saccharomyces boulardii
03
Conditions
preterm birth
Beyond the preview
Go deeper on NCT02310425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02310425.